Does the increase of exosomal microRNAs reflect an activated immune system in melanoma?
Poster Dec 12, 2013
Nina Koliha, Florian S. Dreyer , Jochen Dindorf , Andreas Bosio, Andreas S. Baur , and Stefan Wild
One of the new classes of potential cancer biomarkers are microRNAs. MicroRNAs are non-coding RNAs that suppress the translation of their target mRNAs by binding to the 3’ untranslated region³. On the one hand, melanoma-derived exosomes are discussed as vesicles for degradation of anti-tumor microRNAs. On the other hand, exosomal microRNAs might be active in recipient cells4, e.g., by repressing anti-tumorigenic immune responses. To investigate these possibilities, we profiled the microRNA content of exosomes from melanoma cell lines and plasma of melanoma patients. Informed consent was collected according to guidelines for medical and research ethics.
Despite the developments in conventional PCR, the complexity of multiplex Real Time PCR is still limited due to the lack of sufficient detection channels. To achieve high-end multiplexing capacity on standard Real Time PCR machines, Anapa Biotech has developed the MeltPlex® technology (see box on right).READ MORE
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE